Pharmaceutical Technology on MSN
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results